DIMERIX LIMITED — Interim / Quarterly Report 2012

Jan 24, 2012

==> picture [233 x 87] intentionally omitted <==

25 January 2012

ASX Limited Company Announcements Office Level 4, Stock Exchange Centre 20 Bridge Street SYDNEY NSW 2000

Dear Sir/Madam

Appendix 4C- Quarterly Report

Please find enclosed an Appendix 4C for the period ending 31 December 2011.

Sun Biomedical Limited (ASX: SBN) wishes to advise that the loan advanced pursuant to the Margin Loan Agreement it entered into on 31 July 2011 (as announced on 1 August 2011) which is secured by shares in Malachite Resources Limited, is due to be repaid in full (together with all interest) on 31 January 2012. Upon repayment of the principal and interest, SBN will be entitled to a cash payment of $338,289.

SBN is continuing to investigate and assess a number of potential investment opportunities that will provide the Company and shareholders with a commercial return.

Yours faithfully

==> picture [152 x 75] intentionally omitted <==

Alfonso Grillo Company Secretary

Sun Biomedical Limited ABN 18 001 285 230

ASX:SBN www.sunbiomed.com

Investor Communications Computershare T: +61 1300 850 505 | F: +61 3 9473 2500 | E: info@sunbiomed.com

Appendix 4C Quarterly report for entities admitted on the basis of commitments

le 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity	Name of entity
Sun Biomedical Limited
ABN		Quarter ended (“current quarter”)
18 001 285 230		31 December 2011

Consolidated statement of cash flows

Consolidated statement of cash flows
Cash flows related to operating activities1.1Receipts from customers1.2Payments for(a) staff costs(b) advertising and marketing(c) research and development(d) leased assets(e) other working capital1.3Dividends received1.4Interest and other items of a similar naturereceived1.5Interest and other costs of finance paid1.6Income taxes paid1.7Other (provide details if material)Net operating cash flows	Current quarter$A’000	Year to date(6 months)$A’000
	2--(23)-(51)-2---	2--(63)-(122)-20---
	(70)	(163)

• See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 2

Appendix 4C Quarterly report for entities admitted on the basis of commitments

	Current quarter$A’000	Year to date(6 months)$A’000
1.8Net operating cash flows (carried forward)	(70)	(163)
Cash flows related to investing activities1.9Payment for acquisition of:(a) business (item 5)(b) equity investments(c) intellectual property(d) physical non-current assets(e) other non-current assets1.10Proceeds from disposal of:(a) business (item 5)(b) equity investments(c) intellectual property(d) physical non-current assets(e) other non-current assets1.11Loans to other entities1.12Loans repaid by other entities1.13Other (provide details if material)Net investing cash flows1.14Total operating and investing cash flows	-(251)-----------	-(251)----90---(791)150-
	(251)	(802)
	(321)	(965)
Cash flows related to financing activities1.15Proceeds from issues of shares, options, etc.1.16Proceeds from sale of forfeited shares1.17Proceeds from borrowings1.18Repayment of borrowings1.19Dividends paid1.20Other – Capital raising costNet financing cash flows	------	------
	-	-
Net increase (decrease) in cash held1.21Cash at beginning of quarter/year to date1.22Exchange rate adjustments to item 1.201.23Cash at end of quarter	(321)388-	(965)1,032-
	67	67

• See chapter 19 for defined terms.

Appendix 4C Page 3

30/9/2001

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

		Current quarter
		$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(16)
1.25	Aggregate amount of loans to the parties included in item 1.11

• 1.26 Explanation necessary for an understanding of the transactions Director fees paid to Directors of Sun Biomedical Limited.

Non-cash financing and investing activities

• 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

Not Applicable

• 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Not Applicable

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available	Amount used
		$A’000	$A’000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

• See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 4

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash
Reconciliation of cash at the end of the quarter (as	Current quarter	Previous quarter
shown in the consolidated statement of cash flows) to	$A’000	$A’000
the related items in the accounts is as follows.
4.1Cash on hand and at bank	12	16
4.2Deposits at call	55	372
4.3Bank overdraft	-	-
4.4Other (provide details)	-	-
Total: cash at end of quarter(item 1.22)	67	388

Acquisitions and disposals of business entities

		Acquisitions	Disposals
		(Item 1.9(a))	(Item 1.10(a))
5.1	Name of entity	Not applicable	Not applicable
5.2	Place of incorporation
	or registration
5.3	Consideration for
	acquisition or disposal
5.4	Total net assets
5.5	Nature of business

Compliance statement

• 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act.

• 2 This statement does give a true and fair view of the matters disclosed.

25 January 2012 Sign here: ............................................................ Date: ............................ (Company Secretary)

Alfonso Grillo Print name: .........................................................

• See chapter 19 for defined terms.

Appendix 4C Page 5

30/9/2001

Appendix 4C Quarterly report for entities admitted on the basis of commitments

Notes

1. The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.

   • 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss

   • 9.2 - itemised disclosure relating to acquisitions

   • 9.4 - itemised disclosure relating to disposals

   • 12.1(a) - policy for classification of cash items  12.3 - disclosure of restrictions on use of cash  13.1 - comparative information

3. Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

• See chapter 19 for defined terms.

30/9/2001

Appendix 4C Page 6